蔚蓝生物(603739.SH)：尚无用于抗癌、肿瘤等药物领域的技术储备

Group 1 - The core viewpoint of the article is that Blue Horizon Biotech (603739.SH) currently has no technological reserves for the fields of cancer and tumor drugs [1] Group 2 - The company communicated this information through its investor interaction platform [1] - The statement indicates a lack of development in oncology-related technologies, which may impact future growth prospects in this sector [1]